Potential of gene therapy for the treatment of pituitary tumors

Current Gene Therapy

Volumn 4, Issue 1, 2004, Pages 79-87

  Goya, R G ^a   Sarkar, D K ^b   Brown, O A ^a   Herenu C B ^a,b  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Combined therapy; Estrogen; Gene therapy; Nanotechnology; Neurosurgery; Pituitary tumors; Prolactinomas; Suicide gene therapy; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; CYTOSINE DEAMINASE; DEOXYCYTIDINE KINASE; DIPHTHERIA TOXIN; DNA FRAGMENT; ESTROGEN; GANCICLOVIR; GROWTH HORMONE; PROLACTIN; RETINOBLASTOMA PROTEIN; THYMIDINE KINASE; TYROSINE 3 MONOOXYGENASE;

BRAIN TUMOR; CARCINOGENESIS; CELL COMMUNICATION; CELL SPECIFICITY; GENE THERAPY; GENE TRANSFER; GROWTH INHIBITION; GROWTH STIMULATION; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS INTERMEDIATE LOBE; HYPOPHYSIS TUMOR; MEDICAL RESEARCH; MOLECULAR GENETICS; NANOTECHNOLOGY; NEUROENDOCRINE TUMOR; NONHUMAN; PROLACTINOMA; PROMOTER REGION; REVIEW; RISK BENEFIT ANALYSIS; SUICIDE GENE THERAPY; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HUMANS; MICE; NANOTECHNOLOGY; PITUITARY NEOPLASMS;

ANIMALIA;

EID: 3042783232     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/1566523044578086     Document Type: Review

References (94)

1. Aoki, T., Kato, S., Fox, J.C., Okamoto, K., Morimatsu, M. and Shigemori, M. (2002) Inhibition of autocrine fibroblast growth factor signaling by the adenovirus-mediated expression of an antisense transgene or a dominant negative receptor in human glioma cells. Int. J. Oncol., 21: 629-636.
2. Aronica, S.M. and Katzenellenbogen, B.S. (1991) Progesterone receptor regulation in uterine cells: stimulation by estrogen, cyclic adenosine 3,5-monophosphate and insulin-like growth factor I and suppression by antiestrogens and protein kinase inhibitors. Endocrinology, 128: 2045-2052.
3. Asa, S.L., Kelly, M.A., Grandy, D.K., Low, M.J. (1999) Pituitary lactotroph adenomas develop after prolonged lactotroph hyperpalsia in dopamine D2 receptor-deficient mice. Endocrinology, 140: 5348-5355.
4. Baird, A., Esch, F., Mormede, P., Ueno, N., Ling, N., Bohlen, P., Ying, S.Y., Wehrenberg, W.B. and Guillemin R. (1986) Molecular characterization of fibroblast growth factor: distribution and biological activities in various tissues. In: Greep RO (ed): Recent Progress in Hormone Research, Eds. Greep R.O. Academic Press, New York, pp 143-205.
5. Banerjee, S.K., De, A. and Sarkar, D.K. (1994) Colocalization of prolactin and PCNA within anterior pituitary cells in estrogen treated rats: Evidence for the induction of lactotrope cell proliferation during estrogen induced pituitary tumors. Cancer Letter, 83: 139-14.
6. Beck, C.A., Weigel, N.L. and Edwards, D.P. (1992) Effects of hormone and cellular modulators of protein phosphorylation on transcriptional activity, DNA binding and phosphorylation of human progesterone receptors. Mol. Endocrinol., 6: 607-610.
7. Ben-Jonathan, N. and Hnasko, R. (2001) Dopamine as a prolactin (PRL) inhibitor. Endocr. Rev., 22: 724-763.
8. Bevan, J.S., Webster, J., Burke, C.W. and Scanlon, M.F. (1992) Dopamine agonists and pituitary tumor shrinkage, Endocr. Rev., 13: 220-240.
9. Bevan, J.S., Atkin, S.L., Atkinson, A.B., Bouloux, P.M., Hanna, F., Harris, P.E., James, R.A, McConnell, M., Roberts, G.A., Scanlon, M.F., Stewart, P.M., Teasdale, E., Turner, H.E., Wass, J.A. and Wardlaw, J.M. (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I and tumor size. J. Clin. Endocrinol. Metab., 87: 4554-4563.
10. Bolognani, F., Albariño, C., Romanowski, V., Carri, N.G. and Goya R.G. (2001) In vitro and in vivo herpetic vector-mediated gene transfer in the pituitary gland: impact on hormone secretion, Eur. J. Endocrinol., 145: 497-503.
11. Burek, J.D. (1978) Pathology of aging rats. CRC Press, Boca Raton, FL.
12. Cai, A., Hayes, D.J., Patel, N. and Hyde, J.H. (1999) Targeted overexpression of galanin in lactotropes of transgenic mice induces hyperprolactinemia and pituitary hyperplasia. Endocrinology, 140: 4955-4964.
13. Carol, N., Lauterbach, H., Klinger, G., Unger, A. and Michels, W. (1988). Prolactin stimulation using the metoclopramide test in females taking oral contraceptives. Zentralbl. Gynakol. 110: 1515-1521.
14. Castro, M.G., Goya, R.G., Sosa, Y.E., Rowe, J., Larregina, A.T., Morelli, A.E. and Lowenstein, P.R. (1997). Expression of transgenes in normal and neoplastic anterior pituitary cells using recombinant adenoviruses: long term expression, cell cycle dependency and effects on hormone secretion. Endocrinology, 138: 2184-2194.
15. Castro, M.G., Southgate, T. and Lowenstein, P.R. (2001). Molecular therapy in a model of neuroendocrine disease: developing clinical gene therapy for pituitary tumours. TEM, 12: 58-64
16. Chaidarun, S.S., Klibanski A. and Alexander, J.M. (1997) Tumor-specific expression of alternative spliced estrogen receptor messenger ribonucleic acid variants in human pituitary adenoma. J. Clin. Endocrinol. Metab., 82: 1058-1165.
17. Chaidarun, S.S., Swearingen, B. and Alexander, J.M. (1998) Differential expression of estrogen receptor-β (ERβ) in human pituitary tumors: functional interactions with ERα and a tumor-specific splice variant. J. Clin. Endocrinol. Metab., 83: 3308-3315.
18. Chang, R.J., Keye, W.R., Young, J.R., Willson, C.B. and Jaffe, R.B. (1977) Detection, evaluation and treatment of pituitary microadenomas in patients with galactorrhea and amenorrhea. Am. J. Obstet. Gynecol., 128: 356-363.
19. Chen, R.H., Ebner, R. and Derynck, R. (1993) Inactivation of the type II receptor pathways for the diverse TGF-β activities. Science, 260: 1335-1338.
20. Chun, T., Gregg, D., Sarkar, D.K. and Gorski, J. (1998) Differential regulation by estrogens of growth and prolactin synthesis in pituitary cells suggests that only a small pool of estrogen receptors is required for growth. Proc. Natl. Acad. Sci. USA, 95: 2325-2330.
21. Cruz-Soto, M.E., Scheiber M.D., Gregerson, K.A., Boivin, G.P. and Horseman, N.D. (2002) Pituitary tumorigenesis in prolactin gene-disrupted mice. Endocrinology, 143: 4429-4436.
22. Daniels, G.H. and Martin, J.B. (1995). Neuroendocrine regulation and diseases of the anterior pituitary and hypothalamus. In: Harrison's Principles of Internal Medicine, Eds.
23. Davis, J.R., McMahon, R.F., Lowenstein, P.R., Castro, M.G., Lincoln, G.A. and McNeilly, A.S. (2002) Adenovirus⋯diated gene transfer in the ovine pituitary gland is associated with hypophysitis. J. Endocrinol., 173: 265-271.
24. DeNicola, A.F., Von Lawzewifsch, I.S., Kaplan, E. and Libertum, C. (1978) Biochemical and ultrastructural studies of estrogen-induced pituitary tumors in F344 rats. J. Natl. Cancer Inst., 61: 753-763.
25. DiAugustine, R.P., Petrusz, P., Bell, G.I., Brown, C.F., Korach, K.S., McLachlan, J.A. and Teng, C.T. (1988) Influence of estrogens on mouse uterine epidermal growth factor precursor protein and messenger ribonucleic acid. Endocrinology, 122: 2355-2361.
26. Drexler, K.E., Peterson, C. and Pergamit, G. (1991) Unbounding the Future: The Nanotechnology Revolution. Willian Morrow, New York
27. El-Tanani, M.K.K. and Green, C.D. (1997) Two separate mechanisms for ligand-independent activation of the estrogen receptor. Mol. Endocrinol., 11: 928-937.
28. Enmark, E., Pelto-huikko, M., Grandien, K. Lagercrantz, S., Lagercrantz, J., Fried, G., Nordenskjold, M., Gustafson, J.A. (1997) Human estrogen receptor β-gene structure, chromosomal localization and expression pattern. J. Clin. Endocrinol. Metab., 82: 4258-4265.
29. Fahy, U.M., Foster, P.A., Torodo, H. W., Hartog, M. and Hull, M.G. (1992) The effect of combined estrogen/progesterone treatment in women with hyperprolactinemic amenorrhea. Gynecol. Endocrinol., 6: 183-188.
30. Ferrara, N., Schweigerer, L., Neufeld, G., Mitchell, R. and Gospodarowicz, D. (1987) Pituitary follicular cells produce basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA, 84: 5773-5777.
31. Freese, A., During, M.J., Davidson, B.L., Gennarelli, T.A., Kaplitt, M.G., Flamm, E.S. and Snyder, P.J. (1996) Transfection of human lactotroph adenoma cells with an adenovirus vector expressing tyrosine hydroxylase decreases prolactin release, J. Clin. Endocrinol. Metab., 81: 2401-2404.
32. Freitas, R.A. Jr.: (1999) Nanomedicine. Vol. 1; Landes Bioscience, Palo Alto, CA.
33. Friend, K.E., Chiou, Y.K., Lopes, M.B., Laws, Jr. E.R., Hughes, K.M. and Shupnik, M.A. (1994) Estrogen receptor expression in human pituitary: correlation with immunohistochemistry in normal tissue and immunohistochemistry and morphology in macroadenomas. J. Clin. Endocrinol. Metab., 78: 1497-1504.
34. Garcia, M.M. and Kapcala, L.P. (1995) Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy. J. Endocrinol. Invest., 18: 450-455.
35. Gomez, F., Reyes, F. and Fairman, C. (1977) Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases. Am. J. Med., 62: 648-660.
36. Gooren, L., Assies, J.G., Asscheman, J., deSlegte, A.R. and vanKessel H. (1987) Estrogen-induced prolactinoma in a man. J. Clin. Endocrinol. Metab., 66: 444-446.
37. Gossen, M. and Bujard, H. (1992) Tight control of gene expression in mammalian cells by tetracycline responsive promoters. Proc. Natl. Acad. Sci USA, 88: 5547-5551
38. Goya, R.G., Rowe, J., Sosa, Y.E., Tomasec, P., Lowenstein, P.R. and Castro, M.G. (1998) Use of recombinant herpes simplex virus type I vectors for gene transfer into tumour and normal anterior pituitary cells. Molec. Cell. Endocrinol., 139: 199-207.
39. Green, S., Walter, P., Kumar, V., Bornert, M., Argos, P. and Chambon P. (1989) Human oestrogen receptor cDNA: sequence, expression and homology to V-erb-A. Nature, 320: 134-139.
40. Grigsby, P.W. and Sheline, G.E. (1990) Pituitary. In: Principles and Practice of Radiation Oncology, Eds, Perez C.A. & Bray, L. A. Lippincott, Philadelphia, pp 564-582.
41. Heaney, A.P, Horwits G.A., Wang, Z., Singson, R. and Melmed, S. (1999) Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinomas pathogenesis. Nature Med., 5: 1317-1322.
42. Hentges, S. and Sarkar, D.K. (2001) Transforming growth factor β regulation of estradiol-induced prolactinomas. Rec. Prog. Neuroendocrinol., 22: 340-363.
43. Hentges, S., Boyadjieva, N. and Sarkar, D. K. (2000a) Transforming growth factor-β 3 stimulates lactotrope cell growth by increasing basic fibroblast growth factor from folliculo-stellate cells. Endocrinology, 141: 859-867.
44. Hentges, S., Pastorcic, M., De, A., Boyadjieva, N. and Sarkar, D.K. (2000b) Opposing actions of two transforming growth factor-β isoforms on pituitary lactotropic cell proliferation. Endocrinology, 141: 1528-1535.
45. Herman, Y., Drazin, N.Z., Gonsky, R. and Melmed, S. (1993) Molecular screening of pituitary adenomas for gene mutations and arrangements J. Clin. Endocrinol. Metab., 77: 50-55.
46. Hoganson, D.K., Batra, R.K., Olsen, J.C. and Boucher, R.C. (1996) Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res., 56: 1315-1323.
47. Hu, N., Gutsmann, A., Herbert, D.C., Bradley, A., Lee, W.H. and Lee EY (1994) Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene, 9: 1021-1029.
48. Hsu, D.W., El-Azouzi, M., Black, P.M., Chin, W.W., Hedley-Whyte, E.T., Kaplan, L.M. (1990) Estrogen increases galanin immunoreactivity in hyperplastic prolactin-secreting cells in Fischer 344 rats. Endocrinology, 126: 3159-3167.
49. Ishibashi, M. and Yamaji, T. (1985) Functional heterogeneity of human prolactin-producing pituitary adenoma cells. In: Prolactin basic and clinical correlates, Eds. MacLeod R.M., Scapagnini U., & Thorner M.O. Springer-Verlag, New York, pp 641-702.
50. Karga, H.J., Alexander, J.M., Hedley-Whyte, E.T., Klibanski, A. and Jameson J.L. (1992) Ras mutation in human pituitary tumors. J. Clin. Endocrinol. Metab., 74: 914-919.
51. Katzenellenbogen, B.S. and Gorski, J. (1975) Estrogen actions on synthesis of macromolecules in target cells. In: Biochemical Actions of Hormones, vol. 3 Ed. Litwack L. Academic Press, New York, pp 187-243.
52. Kuiper, G.G.J.M., Enmark, E., Peltottuikko, M., Nilsson, S. and Gustafsson, J.A. (1996) Cloning of a novel estrogen receptor expressed in rat prostrate and ovary. Proc. Natl. Acad. Sci. USA, 93: 5925-5930.
53. Lee, E.J., Thimmapaya, B. and Jameson, J.L. (2000) Stereotactic injection of adenoviral vectors that target gene expression to specific pituitary cell types: Implications for gene therapy. Neurosurgery, 46: 1461-1469.
54. Lee, E.J. and Jameson, J.L. (2002) Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy; Hum. Gene Ther., 13: 533-542.
55. Lee, E.J. anderson, L.M., Thimmapaya, B. and Jameson, J.L. (1999) Targeted expresion of toxic genes directed by pituitary hormone promoters: a potential strategy for adenovirus-mediated gene therapy of pituitary tumors. J. Clin. Endocrinol. Metab., 84: 786-794.
56. Lingham, R.B., Stancel, G.M. and Loose-Mitchell, D.S. (1988) Estrogen regulation of epidermal growth factor receptor messenger ribonucleic acid. Mol. Endocrinol., 2: 230-235.
57. Littley, M.D., Shalet, S.M., Beardwell, C.G., Ahmed, S.R., Applegate, G. and Sutton, M.L. (1991) Hypopituitarism following external radiotherapy for pituitary tumours in adults, Q. J. Med., 70: 145-160.
58. Lloyd, R.V. (1983) Estrogen-induced hyperplasia and neoplasia in the rat anterior pituitary gland. Am. J. Pathol., 113: 198-206.
59. Luciano, A.A., Sherman, B.M., Chapler, F.K., Hauser, K.S. and Wallace, R.B. (1985) Hyperprolactinemia and contraception: a prospective study. Obstet. Gynecol., 65: 506-510.
60. Macilwain C. (2000) Nanotech thinks big. Nature, 405: 730-732.
61. Matsuda, T., Yamamoto, T., Muraguchi, A., Saatcioglu, F. (2001) Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. J. Biol. Chem., 276: 42908-42914.
62. Melmed, S. (1997) General aspects of the management of pituitary tumors by surgery or radiation therapy. In: Endocrinology, Ed. DeGroot L.J. Saunders, Philadelphia, pp. 497-503.
63. Mosselman, S., Polman, J. and Dijkema, R. (1996) ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett., 392: 49-53.
64. Nanotech (2001) Sci. Am. 285(3): 26-83
65. National Nanotechnology Initiative; http://www.nano.gov
66. Páez-Pereda, M., Giacomini, D., Refojo, D., Nagashima, A.C., Hopfner, U., Grübler, Y., Chervin, A., Goldberg, V., Goya, R.G., Hentges, S.T,, Low, M.J., Holsboer, F., Stalla, G.K., Arzt, E.(2003) Involvement of bone morphogenetic protein 4 in prolactinoma pathogenesis: BMP-4 is overexpressed in pituitary prolactinomas and promotes cell growth through a Smad/estrogen receptor cross-talk. Proc. Ntnl. Acad. Sci., 100: 1034-1039.
67. Prior, J.C., Cox, T.A., Fairholm, D., Kostashuk, E. and Nugent, R. (1987) Testerone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. J. Clin. Endocrinol. Metab., 64: 391-394.
68. Riley, D.J., Yu, A., Lee, W-H. (1996) Adenovirus-mediated retinoblastoma gene therapy supresses spontaneous pituitary melanotroph tumors in Rb+/- mice. Nature Med., 2: 1316-1321.
69. Sadoul, J.L., Thyss, A. and Freychet, P. (1992) Invasive mixed growth hormone/prolactin secreting pituitary tumor: complete shrinking by octreotide withdrawal. Acta Endocrinol., 126: 179-183.
70. Sarkar, D.K., Gottschall, P.E. and Meites, J. (1983) Relation of the neuroendocrine system to development of prolactin secreting pituitary tumors. In: Neuroendocrinology of Aging. Ed: Meites J., Plenum Press, New York, pp 353-376.
71. Sarkar, D.K., Gottschall, P.E. and Meites, J. (1982) Damage to hypothalamic dopaminergic neurons is associated with development of prolactin-secreting tumors. Science, 218: 684-686.
72. Sarkar, D.K., Hentges, S.T., De, A., Reddy, R.H.R. (1998) Hormonal control of pituitary prolactin secreting tumors. Frontiers in Bioscience, 3: 934-943.
73. Sarkar, D.K., Kim, K.H. and Minami, S. (1992) Transforming growth factor-β1 mRNA and protein expression in the pituitary gland and its action on PRL secretion and lactotropic growth. Mol. Endocrinol., 6: 1825-1833.
74. Sarkar, D.K., Pastorcic, M., De, A., Engel, M., Moses, H. and Ghasemzadeh, B. (1998) Role of transforming growth factor (TGF)-β type I and TGF-β type II receptors in the TGF-β1-regulated gene expression in pituitary prolactin-secreting lactotropes. Endocrinology, 139: 3620-3628.
75. Schechter, J., Ahmad, N. and Weiner, R. (1988) Activation of anterior pituitary folliculo-stellate cells in the formation of estrogen-induced prolactin-secreting tumors. Neuroendocrinology, 48: 569-576.
76. Schechter, J. and Weiner, R. (1991) Changes in basic fibroblast growth factor coincident with estradiol induced hyperplasia of the anterior pituitaries of Fischer 344 and Sprague-Dawley rats. Endocrinology, 129: 2400-2408.
77. Schuff, K.G., Hentges, S.T., Kelly, M.A., Binart, N., Kelly, P.A., Iuvone, P.M., Asa, S.L. and Low, M.J. (2002) Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanism. J. Clin. Invest., 110: 973-981.
78. Sheppard, M.C. (1994) Aims of treatment and definition of cure. In: Treating Acromegaly- 100 Years On. Ed. Wass J.A.H. Society for Endocrinology, Bristol, pp 17-31.
79. Sherman, B.M., Harris, C.E., Schlechte, J.N., Duello, T.M., Halmi, S., VanGilder, J., Chapler, F.K. and Granner, D.K. (1978) Pathogenesis of prolactin-secreting pituitary adenomas. Lancet, 11: 1019-1021.
80. Shida, N., Ikeda, H., Takashi, Y., Oshima, M., Taketo, M.M. and Miyoshi, I. (1998) Estrogen-induced tumorigenesis in the pituitary gland of TGF-β(+/-) knockout mice. Biochim. Biophys. Acta, 140: 79-83.
81. Shimon, I. and Melmed, S. (1998). Management of pituitary tumors. Annals Int. Med., 129: 472-483.
82. Shull, J.D., Spady, T. J., Snyder, M.C., Johansson, S.L. and Pennington, K.L. (1997) Ovary-intact, but not ovariectomized female ACI rats treated with 17-β estradiol rapidly develop mammary cacinoma. Carcinogenesis, 18: 1595-1602.
83. Shy, K.K., McTiernan, A.M., Daling, J.R and Weiss, N.S. (1983) Oral contraceptive use and the occurrence of pituitary prolactinoma. J. Am. Med. Assoc., 249: 2204-2207.
84. Smith-Arica, J. R., Williams, J. C., Stone, D., Smith, J. Lowenstein, P. R. and Castro, M. G. (2001). Switching on and off transgene expression within lactotrophic cells in the anterior pituitary gland in vivo. Endocrinology, 142: 2521-2532.
85. Southgate, T. D., Stone, D., Williams, J. C., Lowenstein, P. R. and Castro, M. G. (2001) Long-term transgene expression within the anterior pituitary gland in situ: Impact on circulating hormone levels, cellular and antibody-mediated immune responses. Endocrinology, 142: 464-476.
86. Southgate, T.D., Windeatt, S., Smith-Arica, J., Gerdes, C.A., Perone, M.J., Morris I., Davis, J.R., Klatzmarin, D., Lowenstein, P.R. and Castro, M.G. (2000) Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vectors in vitro and in vivo in normal and estrogen/sulpiride-induced hyperplastic anterior pituitaries. Endocrinology, 141: 3493-3505.
87. Sutton, M.L. (1985) Adult central nervous system. In: The Radiotherapy of Malignant Disease, Eds. Easson E.C. & Pointon R.C.S.. Springer, New York, pp 215-236.
88. Tonner, D. and Schlechte, J. (1993) Contemporary therapy of prolactin-secreting adenomas. Am. J. Med. Sci., 306: 395-397.
89. Webster, J., Piscitelli, G., Polli, A., Ferrari, C.I., Ismail, I. and Scanlon, M.F. (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med., 331: 904-909.
90. Weigel N. (1994) Steroid receptors and their regulation by phosphorylation. Ed. Khan S. & Stancel G. CRC Press, Boca Raton, pp 1-12.
91. Wickland, S.A., Werts, N. and Gorski, Jr. (1981) A comparison of estrogen effect on uterine and pituitary growth and prolactin synthesis in F-344 and Holtzman rats. Endocrinology, 109: 1700-1707.
92. Williams, J.C., Stone, D., Smith-Arica, J.R., Morris, I.D., Lowenstein, P.R. and Castro, M.G. (2001) Regulated adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas; Mol. Ther., 4: 593-602.
93. Windeatt, S., Southgate, T.D., Dewey, R.A., Bolognani, F., Perone, M.J., Larregina, A.T., Maleniak, T.C., Morris, I.D., Goya, R.G., Klatzmann, D., Lowenstein, P.R. and Castro, M.G. (2000) Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas. J. Clin. Endocr. Metab., 85: 1296-1305.
94. Zhang, X., Horwitz, G.A., Prezant, T.R., Valentini, A., Nakashima, M., Bronstein, M.D., Melmed, S. (1999) Structure, expression and function of human pituitary tumor-transforming gene (PTTG). Mol. Endocrinol., 13: 156-166.